product image
Neurogene raises $68.5M; AbbVie and Teneobio sign deal; 5AM Ventures nets

Jun 19, 2020

Neurogene raises USD 68.5 Million for rare neurological diseases Neurogene netted USD 68.5 million to advance multiple gene therapy programs in its series A round. The idea...

Read More
product image
The antidepressant drug gets support from FDA

Feb 10, 2020

The hallucinogenic party drug, ketamine has passed the final problem for going into the clinical stage as an antidepressant. The US Food and Drug Administration (FDA), an i...

Read More
product image
Antidepressant of J&J leads to FDA; SCLC model discloses; Genes and macular degeneration can disclose new treatment ways

Jun 17, 2020

The nasal antidepressant of Johnson & Johnson leads to FDA committee The antidepressant esketamine of Johnson & Johnson heads to FDA panel. This might be an end for...

Read More
product image
Raynaud’s Disease -A debilitating condition

Feb 14, 2020

Raynaud’s Disease (RD), also called Raynaud’s phenomenon, is a rare disorder of the blood vessels. The symptoms include when one is feeling cold ...

Read More
product image
Acromegaly

Feb 14, 2020

Read More
product image
Genentech remunerates Xencor; XPrize upraises fund; GSK gambles

Jul 17, 2020

Genentech remunerates Xencor USD 120 Million for global rights Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeut...

Read More
product image
Relation between gut microbes and depression bolstered

Feb 6, 2019

Relations between the central nervous system and the trillions of bacteria in the gut are being targeted for research. What we know so far is based on studies indicating li...

Read More
product image
Notizia

Feb 5, 2020

FDA discards depression drug ALKS 5461 of Alkermes The FDA has rejected approval for ALKS 5461 of Alkermes in major depressive disorder. ALKS 5461 is a fixed-dose combina...

Read More
product image
Myasthenia Gravis

Feb 5, 2020

To get a free sample report, click the link: https://www.delveinsight.com/report-store/myasthenia-gravis-market-insight-epidemiology-and-market-forecast

Read More
product image
Neuroendocrine Tumors (NETs)

Feb 1, 2019

For sample report, click the link below : https://www.delveinsight.com/report-store/neuroendocrine-tumors-nets-market-insights-epidemiology-and-market-forecast

Read More
product image
Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal

Jun 19, 2020

Voyager clears Neurocrine agreement for Parkinson’s gene therapy Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remun...

Read More
product image
Biodesix collaborates with MRM; Avoiding flu with an antibody; Soliris clears trial

Jun 17, 2020

Biodesix collaborates with MRM for development of mass-spec proteomics Biodesix, the lung cancer diagnostic developer is collaborating with MRM Proteomics to authorize its ...

Read More
product image
Molecular Profiling Could Help in Early Lung Cancer Detection: Study

Jul 2, 2020

The world’s first genetic sequencing of precancerous lung lesions could pave the way for very early detection and new treatments report a new study led by UCL researc...

Read More
product image
BridgeBio bags $299M; Immunochina receives $20M; Attune raises; Wren receives $23M

Jun 19, 2020

BridgeBio bags USD 299 Million for genetic diseases BridgeBio Pharma has received a USD299.2 million for its progress in genetic disease pipeline. This includes a...

Read More
product image
‘Software’ differences between humans and monkeys

Jul 3, 2020

The differences between the ‘software’ of humans and monkey brains have been disclosed by neuroscientists for the very first time using a technique that tracks single n...

Read More